Oticon Introduces Oticon More

Oticon, Inc. is challenging the conventions of hearing aid technology once again. The company today launched Oticon More ™, the first-ever hearing aid built with an on-board deep neural network, to give people with mild-to-severe hearing loss a fuller, more balanced and more effortless hearing experience.

The DNN in Oticon More is trained on 12 million real-life sounds to give the brain more of the information it needs to decipher the intricate details of sound. Based on this extensive experiential learning – not on a limited set of man-made rules – it processes speech in noise more like the human brain. This results in a more natural representation of sounds that improves wearers’ speech understanding, reduces listening effort and enables people with hearing loss to remember more of what is being said, even in noisy environments.

“With Oticon More, wearers receive a more natural representation of all sounds,” says Donald Schum, Ph.D., Vice President of Audiology, Oticon, Inc. “The DNN in Oticon More has learned the way the brain learns, naturally over time. Every sound that passes through the hearing aid is compared to the results discovered in the learning phase. This enables Oticon More to provide a more natural, full and precisely balanced sound scene, making it easier for the brain to perform optimally.”

Powerful, more intelligent sound processing

Oticon More with BrainHearing™ technology delivers what the brain needs to make better sense of sound. Built on Oticon’s most intelligent platform yet, Oticon More provides 30% more sound to the brain and improves speech understanding by 15%.*

Industry-leading innovation in sound processing technology ensures Oticon More delivers the information wearers need to decipher sounds and fully engage in any conversation. The hearing aid scans and analyzes the sound scene 500 times per second, capturing and processing the intricate details of sound with better contrast, balance and clarity than ever before.

Oticon More builds on Oticon’s legacy of award-winning product innovation and industry firsts. The hearing aid was recently named a CES® 2021 Innovation Awards Honoree in the Health & Wellness and Wearable Technologies categories.

Connectivity and convenience

Oticon More offers a wide range of connectivity options for a high-quality listening experience in everyday situations. The hearing aid supports direct streaming from iPhone® and select Android™ devices. For people who want the convenience of rechargeable batteries, Oticon More comes in a discreet lithium-ion based rechargeable style (miniRITE R) that provides a full day of battery life**, including streaming, after just three hours of charging.

The new hearing solution is built for individuals with mild-to-severe hearing loss. Wearers can select from eight attractive colors to blend with hair or skin tones.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”